Kala Pharmaceuticals Inc logo

KALA

Kala Pharmaceuticals Inc

$0.32

Earnings Summary

Revenue
$1.37Mn
Net Profits
$-32.94Mn
Net Profit Margins
-2400.95%

Highlights

Revenue:

Kala Pharmaceuticals Inc’s revenue fell -57.99% since last year same period to $1.37Mn in the Q1 2022. On a quarterly growth basis, Kala Pharmaceuticals Inc has generated -26.08% fall in its revenue since last 3-months.

Net Profits:

Kala Pharmaceuticals Inc’s net profit fell -8.32% since last year same period to $-32.94Mn in the Q1 2022. On a quarterly growth basis, Kala Pharmaceuticals Inc has generated 30.75% jump in its net profits since last 3-months.

Net Profit Margins:

Kala Pharmaceuticals Inc’s net profit margin fell -157.84% since last year same period to -2400.95% in the Q1 2022. On a quarterly growth basis, Kala Pharmaceuticals Inc has generated 6.32% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Kala Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.43
EPS Estimate Current Year
-0.43

Highlights

EPS Estimate Current Quarter:

Kala Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.43 - a -19.44% fall from last quarter’s estimates.

EPS Estimate Current Year:

Kala Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.43.

Key Ratios

Key ratios of the Kala Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.45
Return on Assets (ROA)
-0.46
Return on Equity (ROE)
-5.19
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Kala Pharmaceuticals Inc’s earning per share (EPS) jumped 8.16% since last year same period to -0.45 in the Q1 2022. This indicates that the Kala Pharmaceuticals Inc has generated 8.16% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kala Pharmaceuticals Inc’s return on assets (ROA) stands at -0.46.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kala Pharmaceuticals Inc’s return on equity (ROE) stands at -5.19.

Dividend Per Share (DPS):

Kala Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.36
-0.45
-25%

Company Information

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.

Organisation
Kala Pharmaceuticals Inc
Headquarters
Watertown, Massachusetts, US
Employees
188
Industry
Health Technology
CEO
Mark Iwicki